News

Emma will succeed Andrew Witty as GSK CEO, when he retires on 31March 2017. Emma will join the GSK Board of Directors from 1 January 2017. Emma is currently

Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb, said: “The high frequency

In its filing in the US district court of Delaware, Sanofi claims that Merck Sharp & Dohme Corp. violated 10 patents held by it, including ones for its

This indication is based on an increase in dystrophin in skeletal muscles observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not

CYP-001 is Cynata's lead Cymerus mesenchymal stem cell (MSC) product. Cynata plans to conduct the Phase 1 clinical trial, which is entitled "An Open-Label Phase 1 Study to Investigate

Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with

In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core Clinical Development, Regulatory Affairs, and Commercial team and space for

The phase III DURATION-8 trial showed that Bydureon, taken just once a week in combination with Forxiga once daily significantly reduced blood sugar, compared with the individual medicines

The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through